Abstract
Background

Co-morbid type 2 diabetes
Seventy percent of adults with type 2 diabetes also have hypertension or hyperlipidaemia. 1 Subsequently type 2 diabetes is associated with premature CVD 2 and the risk of CVD mortality is higher for people with type 2 diabetes. [3] [4] [5] Furthermore, the UK's largest cause of mortality is CVD, 6 and some argue that a large proportion of these cases are attributed to type 2 diabetes. 7 The impact of polypharmacy in co-morbid diabetes Large randomised controlled trials such as the United Kingdom Prospective Diabetes Study 8 and the Collaborative Atorvastatin Diabetes Study 9 advocate intensive pharmacological management in type 2 diabetes. Most people with type 2 diabetes are prescribed multiple medicines to improve metabolic control, lower serum glucose, cholesterol and blood pressure 10, 11 However, many studies have found that adherence is affected by the frequency of doses and the number of medicines prescribed. 12 For example, Donnan and colleagues found that once daily doses of OADs were associated with better adherence than multiple daily doses. 12, 13 Few studies have examined the effect of multiple medicines from different drug categories. Our previous research has shown that people managing type 2 diabetes and CVD may prioritise some medicines over others, with medicines for hyperlipidaemia management being perceived as less important.
14 When multiple medicines are prescribed, adherence may vary between medicines as a function of the importance patients give them.
What is non-adherence?
behaviourally, performing health-promoting activities (particularly medicine taking) that follow the advice of a healthcare professional can be defined in multiple ways. non-adherence and non-compliance are terms that can be applied to behaviours such as not initiating treatment, not taking medicines as prescribed and terminating treatment prematurely. the World Health Organisation has promoted the use of the term 'adherence' in chronic illness, as it denotes a willingness to take medicines. 15 the term 'adherence' implies that those prescribed medicines are intelligent, active decision-makers, independent and able to take an active role in the management of their condition. 16 Adherence, like many other health behaviours, is a dynamic and multi-faceted concept.
Types of non-adherence to medicines intentional and unintentional non-adherence are two types of non-adherence behaviours. 17 intentional non-adherence is a behaviour driven by a decision not to take medicines. the drivers of this decision are complex but have been suggested to be based on beliefs, personal circumstances, interpretations of healthcare advice and personal motivation. Unintentional nonadherence reflects a person's ability and skill at medicine taking including forgetting, poor manual dexterity, losing medicines or not being able to afford medicines. 18 Few studies of nonadherence in type 2 diabetes take the number of medicines prescribed into account, or distinguish between intentional and unintentional non-adherence. For example, a cross-sectional study showed 57% adherence to glucose-lowering medication, 64% adherence to lipid-lowering medication and 77% adherence to anti-hypertensive medication in participants. 19 However, this study did distinguish between intentional or unintentional non-adherence. intentional non-adherence may have played a larger role in overall non-adherence some medications. More research is needed to investigate the effect of different types of non-adherence across medicines prescribed to those with type 2 diabetes.
Aim
the aim of this study was to examine intentional and unintentional non-adherence mechanisms across increasing numbers OADs, anti-hypertensives and statins in patients with type 2 diabetes. Participants eight hundred and seventy-eight people with type 2 diabetes and CVD were identified from a secondary care diabetes database. Adult patients (aged 18 years and over) were included if they were prescribed one or more OAD, one or more anti-hypertensive, and a statin. People with a care or nursing home address were excluded as they were assumed to have less personal control over taking their medicines than community dwelling populations. People who had not attended the diabetes clinic at the hospital where the study was undertaken within 12 months of the study starting were not approached. this technique improved the response rate and ensured that people were not sent mail from healthcare services with which they had little or no contact.
Materials the number of medicines prescribed for type 2 diabetes, hypertension and hyperlipidaemia was extracted from the local hospital's diabetes register. the number of medicines prescribed was categorised as 3, 4 or 5, and >6.
intentional and unintentional non-adherence across OADs, anti-hypertensives and statins was assessed using the Morisky Medication Adherence Scale (see table 1 ). A five-point Likert scale was used with scores ranging from 0 (total adherence) to 4 (indicating non-adherence). the Morisky scale measures selfreported intentional (two items) and unintentional (two items) non-adherence to medicines. 20 this was repeated three times; once for OADs (as shown in table 1), once for anti-hypertensives and once for statins. therefore, the individual drivers of intentional and unintentional non-adherence for each category of medication could be assessed.
A questionnaire was also used to collect demographic information. the Morisky scale, the demographic information scale and a pre-paid return envelope were posted to potential participants.
Procedure the collaborating diabetologist with consent to access patient medical records used the eligibility criteria to identify eligible adults from the diabetes register based on the medicines prescribed. the diabetes register incorporated prescribing information from secondary and primary care to enhance the quality of data obtained. the Morisky medication adherence scale, a participant information sheet and an invitation letter were sent to eligible subjects. Data from the questionnaires completed and returned were entered into an SPSS database (version 15). 21 
Analysis
A repeated measures AnOVA was used to test the hypothesis that intentional and unintentional non-adherence would differ between categories of medicines prescribed for type 2 diabetes and CVD: this was the within-subjects analysis. the 'categorical number of medicines' variable was used as a between-subjects variable. the between-subject effect of the number of medicines prescribed was examined across the repeated measures analyses for intentional and unintentional non-adherence.
Results
Response rate
Following the first mailing two reminders were sent to increase the response rate, each two weeks apart from one another. the first mailing directly approached 855 people and 480 questionnaires were returned after three postal mailings (one initial mailing and two reminders). Forty-two people returned a blank questionnaire or declined participation directly. the final response rate for this study was 56% (n=480).
Demographics
Participants' mean age was 66.3 years (range: 28-94 years), with 64.6% male (data were missing in three cases); 91.7% white, 1.8% Asian, and 0.4% from other backgrounds. Data on ethnicity were missing for 25 cases. Unintentional non-adherence the within-subject effect for unintentional non-adherence across medicines was significant F(2,409) = 20.201, p≤0.001, partial eta squared = 0.090). Unintentional non-adherence significantly varied between OADs, anti-hypertensives and statins. therefore, unintentional non-adherence was higher for some medicines than for others. Post-hoc analyses revealed that the difference in unintentional non-adherence between OADs and anti-hypertensives was significant (mean difference = 0.404, p≤0.001, Ci(95%) 0.288-0.521); unintentional nonadherence to OADs was higher. Unintentional non-adherence was significantly higher for OADs when compared with statins (mean difference = 0.341, p=0.000, Ci(95%) 0.209-0.474). the difference between unintentional non-adherence to antihypertensives and statins was not significant (mean difference = -0.063, p=0.287, Ci(95%) -0.181 to -0.056)<AQ3>. For people prescribed multiple medicines for type 2 diabetes, unintentional non-adherence to OADs was found to be significantly higher than for any other prescribed medicines. Participants were allocated to groups based on the number of medicines prescribed: 232 people were prescribed three medicines; 102 people were prescribed four or five medicines; 146 people were prescribed six or more medicines. these categories formed the between-subjects variable.
When the between-subjects variable was added to the analysis of unintentional non-adherence the number of medicines prescribed was found to have a significant effect (F(2,410) = 3.010, p=0.050, partial eta squared = 0.014). Unintentional non-adherence decreased as the number of medicines prescribed increased (see figure 1) but the interaction was not Sulphonylureas and beta-blockers had not been prescribed to study participants significant (F(4,818) = 0.744, p=0.562), therefore, the betweensubjects effect was consistent across all categories of medicines; no one medicine type was particularly affected by the number of medicines prescribed. <AQ3>
Intentional non-adherence the repeated measure AnOVA measuring the within-subject effect for intentional non-adherence was not significant (F(2,410) = 2.437, p=0.890) therefore intentional non-adherence did not vary between categories of medicines prescribed for type 2 diabetes with CVD. <AQ3> the between-subjects effect was not significant (F(2,411) = 2.028, p=0.133). therefore, intentional non-adherence did not differ in participants prescribed more medicines. the interaction was significant (F(4,820) = 2.427, p=0.046, partial eta squared = 0.012) with intentional non-adherence to statins changing as six or more medicines were prescribed. this means that for those taking larger numbers of medicines more decisions not to take statins were made (see figure 2) ; but this effect did not occur for OADs or anti-hypertensive medicines. <AQ3> Discussion the key finding of this study is that a significant difference in unintentional non-adherence was found between OADs, antihypertensives and statins. Unintentional non-adherence was higher for OADs than anti-hypertensives and statins, while antihypertensives and statins had similar levels of unintentional non-adherence.
this study found that unintentional non-adherence decreased as more medicines were prescribed, suggesting that forgetting decreased for those prescribed greater numbers of medicines. Furthermore, this effect was consistent across all categories of medicines. the possible reason for this finding is that increased vigilance exists among people managing high numbers of medicines. the use of dosette boxes, greater contact with healthcare professionals and greater disease severity may be factors which influence this finding. the range of strategies to manage regimen complexity has been reported elsewhere; 22, 23 it is likely that people used a range of strategies to facilitate adherence in this complex regimen too. Precise examination of these strategies may help improve adherence in complex regimens.
Previous research has drawn the distinction between intentional and unintentional non-adherence. Our research suggests that people with type 2 diabetes and CVD prescribed multiple medicines may vary in their unintentional non-adherence, with medicines for type 2 diabetes being the most likely to be forgotten. Less variance between medicines was observed for intentional non-adherence, however, when the number of medicines prescribed was high greater variance was observed, particularly around taking statins. this study shows that deliberate and accidental non-adherence varied by the number of medicines prescribed, with deliberate non-adherence increasing for statins only, and accidental non-adherence decreasing as more medicines were prescribed.
Unintentional non-adherence was higher for OADs; this may be because medicines for type 2 diabetes are more likely to be prescribed as multiple doses. the increased number of doses for OADs may have increased missed doses; further research should examine whether people have difficulties managing midday doses (possibly because of work or social commitments). Further research should also focus on whether the differences in intentional and unintentional non-adherence are maintained when daily doses as opposed to the number of medicines prescribed are examined. Key: OAD = oral antidiabetic drug.
Achieving besT PRAcTice
As more medicines were prescribed, non-adherence to statins increased in this study; statins were the only medication to remain consistent across the sample obtained; all participants were prescribed one type of statin. OADs and antihypertensives did increase in number, but remained unaffected by non-adherence decisions. Statins appear to be vulnerable to non-adherence decisions when increasing numbers of medicines are prescribed. Our previous research found that OADs and hypertensive medicines are prioritised above statins by patients. it seems as regimens become more complex then medicines which are undervalued become more vulnerable to non-adherence.
14 Clinicians should recognise that by intensifying the management of type 2 diabetes by increasing OADs or anti-hypertensives, adherence to statins may be compromised.
Limitations
the participants were from a narrow range of ethnic backgrounds, limiting the generalisability of these findings. the sample was drawn from a population of largely elderly people (mean age 66.3 years) who had a range of long-term conditions. the focus of this investigation was type 2 diabetes and CVD but the people who participated may have been taking other medicines; therefore, the presence of other co-morbidities may have influenced the way medicines were managed for some participants. in addition, there are limitations in the use of self-report measures to examine adherence; over-reporting of non-adherence may have been a problem. Also, some participants may have felt threatened by they way that questions on the Morisky adherence scale are phrased. For example, one question indicates carelessness, which could be interpreted by participants as an accusation or culpability for poor self-management. the potential for questionnaire items to generate negative feeling among participants may have led to underreporting of non-adherence on some questionnaire items. Hypothetically there may be implications of repeating questions on non-adherence for three types of medicines. However, further research is needed to examine the effect of repeated questioning on the reliability and validity of responses to adherence items.
Future research should make attempts to distinguish between intentional and unintentional non-adherence and specify which type of adherence is being measured.
